Analyst Ratings for Blueprint Medicines
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 15 analysts have published their opinion on Blueprint Medicines (NASDAQ:BPMC) stock. The average price target is $69.07, implying an upside from the current price of $58.09. This average has increased by 19.46% from the previous average price target of $57.82.
July 14, 2023 | 3:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have given an average price target of $69.07 for Blueprint Medicines, implying an upside from the current price of $58.09.
The average price target given by analysts suggests a potential upside for Blueprint Medicines. This is likely to have a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100